Research Explorer

Project

The role of ZEB transcription factors in malignant progression and therapy resistance in high grade serous ovarian cancer
Code
01D39116
Duration
01 October 2016 → 15 May 2021
Funding
Regional and community funding: Special Research Fund
Promotor
Research disciplines
  • Natural sciences
    • Genetics
    • Systems biology
  • Medical and health sciences
    • Endocrinology and metabolic diseases
    • Gynaecology and obstetrics
    • Laboratory medicine
    • Molecular and cell biology
    • Morphological sciences
    • Oncology
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other basic sciences
    • Endocrinology and metabolic diseases
    • Gynaecology and obstetrics
    • Laboratory medicine
    • Morphological sciences
    • Oncology
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other clinical sciences
    • Other health sciences
    • Nursing
    • Other paramedical sciences
    • Endocrinology and metabolic diseases
    • Gynaecology and obstetrics
    • Laboratory medicine
    • Molecular and cell biology
    • Morphological sciences
    • Oncology
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other translational sciences
    • Other medical and health sciences
Keywords
Ovarian cancer
 
Project description
 

Epithelial ovarian cancer is the most lethal of all gynecologic malignancies. This poor prognosis is mainly due to a delayed diagnosis resulting in advanced stage of disease and frequent therapy-resistant relapses.  We will address the role of the EMT (epithelial mesenchymal transition) inducing transcription factors ZEB1 and ZEB2 in tumor initiation, progression, metastasis and therapy-resistance in high-grade serous ovarian carcinoma.